RxSight (RXST) Q1 2026 earnings review
Core Growth Engine Stalls as Capital Placements Collapse
RxSight's first-quarter 2026 results confirm a deteriorating operational trajectory. The company's strategic pivot toward driving utilization on existing equipment failed to offset a severe capital spending freeze, sending revenue down 18.5% YoY to $30.9 million. Most alarmingly, Light Adjustable Lens (LAL) volumes, the company's high-margin consumable engine, turned negative for the first time (-0.4% YoY). With operating expenses swelling to $41.3 million, net loss nearly doubled YoY to $15.9 million. Full-year guidance cements a bleak outlook, projecting a 5% revenue contraction at the midpoint and a sharp 500+ basis point drop in gross margins.
🐂 Bull Case
Gross margin expanded to 76.1% in Q1 from 74.8% a year ago. The severe drop in low-margin capital equipment sales resulted in a highly favorable product mix skewed toward LALs, providing temporary protection to the gross profit line.
At ASCRS, new meta-analyses and data showing 93.1% of patients achieving simultaneous 20/20 distance and J1 near vision reinforce the product's clinical superiority, establishing a strong foundation for future adoption once macro headwinds subside.
🐻 Bear Case
The entire strategic pivot relied on increasing LAL procedure volume to offset plunging capital sales. A 0.4% decline in LAL units this quarter proves the utilization strategy is struggling to gain traction.
Management expects to push forward with heavy investments (OpEx at the high end of $150-$160M) while revenue falls. Combined with guided margin compression in the back half of the year, cash burn will accelerate.
⚖️ Verdict: 🔴
Bearish. The 'same-store' utilization strategy is failing to cushion the blow of a collapsed capital equipment cycle. With LAL growth Reversing into negative territory and operating leverage violently unwinding, the near-term setup is heavily impaired.
Key Themes
Capital Collapse Contradicts Management Optimism
In the press release, CEO Ron Kurtz cited 'encouraging stabilizing business trends.' This narrative directly contradicts the underlying data: Light Delivery Device (LDD) sales experienced an Accelerating collapse, plunging to just 20 units from 73 a year ago (-73% YoY) and down sequentially from 25 units in Q4. Capital deployment by practices has essentially frozen.
Cost Structure Disconnected From Demand
Management is failing to adjust to the new revenue reality. Operating expenses grew 6% YoY to $41.3 million, vastly exceeding the $30.9 million in revenue. This caused the Loss from Operations to widen severely from $10.7M a year ago to $17.8M today. The deliberate decision to maintain peak-cycle spending during a contraction introduces heavy financial risk.
Macroeconomic Squeeze on Premium Electives
The Premium Intraocular Lens (IOL) market is highly sensitive to consumer sentiment and wealth effects. Patients are increasingly balking at out-of-pocket upcharges, confirming that the broader industry headwinds cited in 2025 have solidified into a persistent drag on the company's total addressable market.
Clinical Efficacy and Technological Superiority
Despite commercial challenges, the core technology continues to deliver. Multiple ASCRS presentations demonstrated the high precision of the Light Adjustable Lens system, including a meta-analysis proving 91.2% accuracy within 0.50 diopters of target refraction. This sustained clinical superiority acts as a primary driver for defending existing market share against new competitive multifocal entrants.
Untapped Capacity in Existing Installed Base
With 1,154 LDD units currently installed, the company is shifting away from new placements and toward intensive practice engagement programs to drive 'same-store' LAL growth. If successful, converting low-utilizing practices into high-volume champions represents the most realistic path back to top-line expansion.
Favorable Shift Toward High-Margin Consumables
The sharp decline in LDD sales has created a mix shift heavily favoring the Light Adjustable Lens (LAL). Because the LAL is a higher-margin consumable, this shift drove Q1 gross margins to an impressive 76.1%. While this dynamic is defensive, it protects near-term gross profitability.
Other KPIs
Stable compared to 74.8% in 25Q1. The margin profile remains strong solely due to the collapse of lower-margin capital sales, leaving the mix heavily concentrated in high-margin LAL consumables. This margin is set to deteriorate based on guidance.
Down from $228.1M in 25Q4. While the balance sheet remains well-capitalized with cash, equivalents, and short-term investments, the Accelerating operating losses will increase the quarterly cash burn rate significantly compared to 2024 and 2025.
Guidance
Decelerating. Implies a ~5% YoY decline at the midpoint ($127.5M) compared to FY25's $134.5M. This confirms that management anticipates prolonged weakness in both LDD capital placements and sluggish LAL procedure volumes.
Decelerating. A severe step-down from the 76.6% achieved in 2025 and the 76.1% seen in 26Q1. Management previously noted this compression is driven by the sell-through of higher-cost inventory due to lower production levels.
Accelerating relative to sales. Despite targeting a 5% revenue contraction, management is committing to maximum guided spend to fund strategic growth initiatives and commercial team expansions, prioritizing long-term market building over near-term cash flow.
Key Questions
LAL Utilization Ceiling
With LAL procedure volumes turning slightly negative (-0.4% YoY) this quarter, how much of this reflects macro weakness versus a natural ceiling on 'same-store' utilization within the existing installed base?
Margin Contraction Timeline
Given that Q1 gross margins were robust at 76.1%, but full-year guidance sits at 70-72%, can you outline the exact quarter-by-quarter margin drag expected as higher-cost inventory begins to flow through the P&L?
OpEx Realignment
Operating expenses are running at a >$160M annualized pace while revenue is shrinking. Under what specific conditions would management consider aggressive cost-cutting to align the expense structure with the current demand environment?